Identification | More | [Name]
AMINOGUANIDINE HEMISULFATE | [CAS]
996-19-0 | [Synonyms]
1-AMINOGUANIDINIUM SULFATE AMINOGUANIDINE HEMISULFATE AMINOGUANIDINE HEMISULFATE SALT AMINOGUANIDINE SULFATE BIS(1-AMINOGUANIDINIUM) SULFATE BIS(1-AMINOGUANIDINIUM) SULPHATE HYDRAZINECARBOXIMIDAMIDE HEMISULFATE hydrazinecarboximidamide,sulfate(2:1) di(carbazamidine) sulphate AMINOGUANIDINE HEMISULFATE CRYSTALLINE guanylhydrazine hemisulfate salt Di(carbazamidin)sulfat Amidinohydrazine hemisulfate | [EINECS(EC#)]
213-628-7 | [Molecular Formula]
C2H14N8O4S | [MDL Number]
MFCD00035665 | [Molecular Weight]
246.25 | [MOL File]
996-19-0.mol |
Safety Data | Back Directory | [Safety Statements ]
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
2
| [HS Code ]
29280000 | [Toxicity]
LD50 orally in Rabbit: > 2000 mg/kg |
Hazard Information | Back Directory | [Chemical Properties]
WHITE CRYSTALS OR CRYSTALLINE POWDER | [Uses]
NO synthase inhibitor | [Application]
Aminoguanidine hemisulfate is used in the treatment of patients with chronic granulomatous disease, which is a form of leukemia. This drug also has been shown to inhibit follicular growth and nitrogen atoms, as well as to inhibit the production of protein-bound polyamines. It was found to have no effect on the intracellular calcium concentration or on growth factor release by receptor cells. It has been shown that it can inhibit cyclase activity and therefore reduce proliferation of cells in experimental models. The ester hydrochloride salt of this compound is an inhibitor of guanylate cyclase, which prevents the conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). | [Biochem/physiol Actions]
Inhibits both constitutive and inducible nitric oxide synthetase |
|
|